<DOC>
	<DOC>NCT01120600</DOC>
	<brief_summary>The purpose of this study is to test the hypothesis that treatment with odanacatib will result in increased BMD (bone mineral density) compared to treatment with placebo. This study will also evaluate the safety and efficacy of odanacatib for male osteoporosis patients.</brief_summary>
	<brief_title>A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)</brief_title>
	<detailed_description>The original study was divided into two parts, with the primary analysis of endpoints to occur at 24 months and the patients will then remain in the study for an additional 12 months (Part 2). Amendment 1 of the protocol removed the additional 12 month period and the Month 36 BMD analysis was deleted.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Has osteoporosis Has anatomy suitable for dual energy xray absorptiometry (DXA) scan of the lumbar spine and and hip Is ambulatory Is currently on oral bisphosphonates or other treatment for osteoporosis Had previous hip fragility fracture and is a candidate for standard of care therapy Has had a fragility fracture (vertebral or nonvertebral fractures indicating reduced bone strength) within 12 months Has had more then one previous vertebral fracture Has been diagnosed with metabolic bone disorder other than osteoporosis Is Vitamin D deficient Has a history of renal stones Has active parathyroid disease Has history of thyroid disease not well controlled by medication Is diagnosed with secondary osteoporosis Has a daily calcium intake of &lt;1,200 mg and is unwilling to take study prescribed supplements or increase dietary intake, such that his daily calcium intake is at least 1200 mg Has a history of malignancy â‰¤5 years prior to signing informed consent Has been diagnosed with hypogonadism due to causes that affect multiple organ and body systems</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>